Daxor Corporation
NASDAQ:DXR · NASDAQ Capital Market
+$0.33 today
Vol 0.00M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
20.0%
avg -2.0%
ROIC
20.0%
avg 0.3%
ROA
19.9%
avg -0.3%
Analysis
ROIC is currently the strongest return metric at 20.0% versus its period average of 0.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Lynn Jefferies FACC | Chief Medical Officer | $299,476.00 | — | 55 | $23,557.00 | 0.47% |
Robert J. Michel | Chief Financial Officer, Chief Compliance Officer & Corporate Secretary | $151,392.00 | — | 69 | $21,050.00 | 0.42% |
Jonathan Adam Feldschuh | Chief Scientific Officer & Director | $151,388.00 | — | 61 | $213,694.00 | 4.24% |
Michael Richard Feldschuh | Chairman, President & Chief Executive Officer | $100,925.00 | — | 57 | $213,694.00 | 4.24% |
Linda Cooper | Vice President of Development & Operations | — | — | — | — | — |
Kathryn A. Kornafel | Senior Vice President of Marketing & Commercial Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$18,970.00
Sells
0
$0.00
Net Sentiment
+$18,970.00
Net buying
Most Active
Jefferies John
3 transactions
Analysis
Insiders reported 7 buys worth $18,970.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $18,970.00. Jefferies John was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Adagene Inc.
NASDAQ:ADAG
$132.15M
Gain Therapeutics, Inc.
NASDAQ:GANX
$76.35M
Great Elm Group, Inc.
NASDAQ:GEG
$73.69M
Adicet Bio, Inc.
NASDAQ:ACET
$72.54M
XBiotech Inc.
NASDAQ:XBIT
$71.65M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$68.62M
CervoMed Inc.
CRVO
$41.85M
Nephros, Inc.
NEPH
$34.63M
Lite Strategy, Inc.
LITS
$31.30M
HeartBeam, Inc.
BEAT
$24.94M
Who manages DXR?
Daxor Corporation (DXR) lists 6 active executives. The top listed executive is Jonathan Adam Feldschuh, Chief Scientific Officer & Director.
Are DXR insiders buying or selling?
Recent insider activity shows net selling of $1.03M.
Explore More
Continue the stock analysis
Jump to another research area for this company.